S-1/A: Drugs Made In America II Launches $500M Pharma SPAC IPO

Drugs Made In America Acquisition II Corp. launches a $500 million initial public offering to target pharmaceutical companies, emphasizing domestic supply chain resilience.

Summary

• Drugs Made In America Acquisition II Corp. is a newly incorporated Cayman Islands exempted company, a blank check company, formed to effect a business combination with one or more businesses.
• The company intends to raise $500,000,000 through the sale of 50,000,000 units at $10.00 per unit in its initial public offering (IPO).
• Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon consummation of an initial business combination.
• An additional 1,200,000 private units will be purchased by the sponsor and Cantor Fitzgerald & Co. for $12,000,000 simultaneously with the IPO closing.
• The company aims to focus its search for business combination targets within the pharmaceutical industry, specifically on companies that can enhance U.S. medical supply chain resilience and reduce reliance on foreign production.
• The strategic goal is to create a fully integrated, competitive cost business with end-to-end capability from plant-based raw material production for controlled substances (APIs) to drug manufacturing and direct patient prescriptions.
• The company has 24 months from the closing of the offering to complete an initial business combination.
• Public shareholders will incur immediate and substantial dilution of approximately 112.40% (or $11.24 per share, assuming no over-allotment exercise and maximum redemption) upon the closing of this offering due to the nominal price paid by the sponsor for founder shares.
• The company reported a net loss of $97,400 for the six months ended June 30, 2025, and a net loss of $151,719 for the period from August 23, 2024 (inception) through December 31, 2024.
• As of June 30, 2025, the company had $4,394 in cash and a working capital deficiency of $315,944.

Sentiment

Score: 4

Explanation: While the management team has relevant experience and a clear strategic focus on a critical industry (U.S. pharmaceutical supply chain resilience), the inherent risks of a SPAC, significant dilution for public shareholders, and past/ongoing legal and bankruptcy issues involving the CEO's prior company (Bright Green Corp.) introduce substantial uncertainty and potential for adverse outcomes. The conflicts of interest due to management's involvement in another SPAC also weigh negatively.

Positives

• The management team possesses extensive experience and a broad network within the pharmaceutical industry, which is expected to aid in identifying suitable acquisition targets.
• The company's strategic focus on mitigating U.S. medical supply chain risks and reducing reliance on foreign pharmaceutical production aligns with current national initiatives and addresses a critical need.
• The business model aims for end-to-end capability from raw material production to finished generic drugs, potentially disrupting the market with competitive costs and enhanced supply chain resilience.
• The target market for plant-based production, API, and generic medications is estimated at $44 billion, offering significant growth potential for a successful business combination.
• The company intends to leverage advanced technology, including AI in controlled environments, for energy-efficient and continuous manufacturing processes for critical drugs.

Negatives

• The company is a blank check company with no operating history, revenues, or identified target business, making it a highly speculative investment.
• Public shareholders will experience immediate and substantial dilution (approximately 112.40% or $11.24 per share) due to the nominal price paid by the sponsor for founder shares.
• Management's involvement in another SPAC (Drugs Made In America Acquisition Corp. DMAA) and prior business issues (Bright Green Corporation's Chapter 11 bankruptcy and ongoing litigation) present potential conflicts of interest and reputational risks.
• There is intense competition for attractive SPAC targets, which could increase acquisition costs or lead to an inability to find a suitable business combination within the 24-month timeframe.
• The company may complete a business combination even if a majority of public shareholders do not support it, as founder shares will participate in the vote and only a small percentage of public shares are needed for approval.
• The ability of public shareholders to redeem shares could make the company's financial condition unattractive to potential targets, hindering deal completion or forcing less desirable terms.
• Deferred underwriting commissions create an incentive for underwriters to complete a business combination, potentially with a riskier target, as these fees are only paid upon deal consummation.
• The company may seek acquisition opportunities with early-stage or financially unstable businesses, which carry inherent operational and financial risks.

Risks

• No operating history, revenues, or identified operating business as a target, providing no basis to evaluate the ability to achieve business objectives.
• Public shareholders may not have an opportunity to vote on the proposed business combination, and even if a vote is held, founder shares' participation may lead to approval despite public shareholder dissent.
• If shareholder approval is sought, initial shareholders, directors, and officers have agreed to vote in favor, making approval more likely regardless of public shareholder sentiment.
• Potential target businesses may gain leverage in negotiations due to the 24-month completion window, potentially leading to less favorable terms.
• The search for a business combination may be adversely affected by global health crises, geopolitical conflicts (Russia-Ukraine, Middle East), and the status of debt and equity markets.
• Changes in the market for directors and officers liability insurance could increase costs and difficulty in completing a business combination.
• Underwriters' deferred underwriting commissions create potential conflicts of interest in providing additional services related to a business combination.
• Inability to complete an initial business combination within the 24-month completion window would result in liquidation, with public shareholders receiving approximately $10.00 per share (or less in certain circumstances) and rights expiring worthless.
• Purchases of shares or rights by initial shareholders, directors, officers, or affiliates may influence a vote on a proposed business combination and reduce public float.
• The company may acquire a target that does not fully meet its stated investment criteria and guidelines.
• Acquisition of an early-stage, financially unstable, or unproven business carries numerous inherent risks.
• Resources may be wasted on researching uncompleted acquisitions, adversely affecting subsequent search efforts.
• Lack of limitation to a particular industry, sector, or geography means investors cannot ascertain specific target business risks.
• Shareholders may fail to receive notice or comply with procedures for redemption, leading to unredeemed shares.
• Shareholders have no rights or interests in trust account funds except under limited circumstances, potentially forcing sales at a loss.
• Nasdaq delisting risk could limit trading and subject the company to additional restrictions.
• Not entitled to certain protections afforded to investors in Rule 419 blank check offerings.
• Annual general meeting may be delayed until after business combination, delaying director appointments.
• Limited resources and significant competition for business combination opportunities may hinder completion.
• Insufficient funds outside the trust account could prevent operations until the completion window ends.
• Past performance of the management team is not indicative of future performance.
• Acquisition targets may be outside management's areas of expertise, increasing risk.
• Management's time allocation to other businesses may negatively impact the ability to complete a business combination.
• Dependence on a small group of individuals (directors and officers); their departure could adversely affect operations.
• Key personnel may negotiate employment/consulting agreements with a target, creating conflicts of interest.
• Limited ability to assess target business management, potentially leading to management lacking public company experience.
• Directors and officers of an acquisition candidate may resign post-combination, negatively impacting operations.
• Affiliations of initial shareholders, directors, and officers with other entities (e.g., DMAA) create conflicts of interest in presenting business opportunities.
• Potential for engaging in business combinations with affiliated entities, raising conflicts of interest.
• Involvement of management in past/current litigation or investigations (e.g., Bright Green Corp. Chapter 11, Fikany litigation) could divert attention and negatively affect reputation.
• Nominal purchase price paid by sponsor for founder shares results in significant dilution for public shareholders and substantial profit potential for the sponsor even if share price declines.
• Conflict of interest for initial shareholders due to loss of entire investment if business combination is not completed.
• Insufficient funds to satisfy indemnification claims of directors and officers.
• Issuance of notes or other debt to complete a business combination may adversely affect leverage and financial condition.
• Completion of only one business combination may lead to lack of diversification and increased risk.
• Seeking complex business combination opportunities requiring significant operational improvements could delay or prevent desired results.
• Management may not maintain control of a target business after the initial business combination.
• Absence of a specified maximum redemption threshold may allow completion of a business combination despite substantial shareholder disagreement.
• Changes in laws or regulations (e.g., 2024 SPAC Rules, U.S. federal excise tax) or failure to comply could adversely affect the business.
• Ability to amend charter documents or governing instruments more easily than some other blank check companies, potentially facilitating an undesirable business combination.
• Uncertain or adverse U.S. federal income tax consequences for investors, including PFIC status.
• Share price of the combined company may decline after the initial business combination.
• Business combination structure may not be tax-efficient, potentially leading to tax obligations for shareholders.
• Reincorporation or transfer to another jurisdiction may result in taxes for shareholders or right holders.
• Cyber incidents or attacks could result in information theft, data corruption, operational disruption, and/or financial loss.

Future Outlook

The company intends to identify, acquire, and accelerate the growth of a pharmaceutical company in the United States. The strategy focuses on mitigating U.S. medical supply chain risks, reducing reliance on foreign production, and developing end-to-end capabilities from plant-based raw materials to finished generic drugs. The post-business combination company aims to grow revenues from the estimated $44 billion plant-based production segment, API market, and generic medications. The company expects to incur increased expenses as a public company for legal, financial reporting, accounting, and auditing compliance, as well as due diligence.

Management Comments

• We have assembled a strong management team with a broad network of connections and corporate relationships across the pharmaceutical industry.
• We are confident that we will be able to use our individual experiences as well as our networks to achieve success.
• We will formulate an all-encompassing plan for growth, one that accounts for both organic expansion and expansion via mergers and acquisitions.
• We will attempt to transform our target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion.
• We will endeavor to generate excellent returns for our shareholders.
• We believe our management team is well positioned to take advantage of the growing set of investment opportunities focused on the pharmaceutical industry.
• Our extensive existing relationships with portfolio companies along with our ongoing efforts to identify investment opportunities will allow us to generate an attractive transaction for our shareholders.
• We believe our sponsor's expertise and track record in the pharmaceutical space will help mitigate legal and regulatory factors by proactively advising potential target companies.
• We believe that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America's overreliance on production of pharmaceuticals from concentrated geographic regions.
• We believe that we have an important role in the future of the pharmaceutical business.
• The complete solution will aim to provide supply chain resilience while mitigating identified national health and security risks.
• We believe that the deliverable of the post-business combination company over a lifecycle from seed to the finished generic drug, delivered to the pharmacy or patient directly, could mitigate an identified national security risk.
• We believe that the post-business combination company will be able to become a new competitive cost producer of drugs made in America.

Industry Context

The company's strategy is directly aligned with addressing critical vulnerabilities in the U.S. medical supply chain, particularly the over-reliance on foreign and geographically concentrated sources for medications and raw materials. This focus is supported by findings from the U.S. Senate Committee Homeland Security and Governmental Affairs in March 2023, which highlighted persistent drug shortages and their cascading effects on patient care and healthcare costs. By targeting the estimated $44 billion plant-based production segment, API market, and generic medications, the company aims to capitalize on initiatives to onshore pharmaceutical production, create jobs, and enhance national healthcare security through a resilient, domestic supply chain. The emphasis on advanced technology and AI in manufacturing also positions the company within broader industry trends towards innovation and efficiency.

Corporate Governance

Legal Proceedings

• Bright Green Corp. (BGXX), a company founded and run by CEO Lynn Stockwell, entered into a Restructuring Support Agreement on January 27, 2025, and filed a voluntary petition for Chapter 11 bankruptcy on February 22, 2025. The Chapter 11 proceeding is ongoing.
• In January 2021, BGXX filed a complaint against John Fikany. Mr. Fikany counterclaimed against Lynn Stockwell and John Stockwell, alleging wrongful termination, fraud in the inducement, negligent misrepresentation, and breach of contract. In August 2024, the court determined an oral agreement existed for Mr. Fikany to work as CEO, and BGXX was not entitled to cancel his shares. BGXX plans to appeal this determination. A jury trial on the counterclaim was set for February 2025 but was vacated and has not been reset. BGXX plans to file motions opposing Mr. Fikany's claims in the Chapter 11 proceeding.

Related Party Transactions

• Drugs Made In America Acquisition II LLC (the sponsor) purchased 14,375,000 founder shares for an aggregate price of $35,000 (approximately $0.0024 per share).
• The sponsor and Cantor Fitzgerald & Co. committed to purchase an aggregate of 1,200,000 private units for $12,000,000 in a private placement.
• The company will pay its sponsor or an affiliate $10,000 per month for office space, administrative, and support services until a business combination or liquidation.
• The sponsor loaned the company up to $325,000 under an unsecured promissory note to cover offering-related and organizational expenses; $297,292 was outstanding as of June 30, 2025.
• The company's CFO, Glenn Worman, is a partner in an advisory firm that provides accounting services to the company, incurring $8,755 in expenses for the six months ended June 30, 2025.
• John Stockwell, husband to CEO Lynn Stockwell, serves as an uncompensated special advisor, counseling on pharmaceutical investment strategies, industry trends, and regulatory considerations.

Stakeholder Impact

• **Shareholders:** Public shareholders face immediate and substantial dilution from founder shares. Their investment is subject to the risk of not completing a business combination, leading to liquidation at approximately $10.00 per share (or less). Redemption rights are available but limited for 'Excess Shares'.
• **Employees:** The company currently has no full-time employees prior to a business combination. Post-combination, the impact on employees will depend on the target business and integration strategy.
• **Customers:** The company's strategic focus on domestic pharmaceutical production aims to benefit U.S. patients and healthcare providers by addressing drug shortages and enhancing supply chain resilience.
• **Suppliers:** The company's strategy to onshore production could create new opportunities for domestic suppliers in the pharmaceutical raw materials and manufacturing sectors.
• **Creditors:** Funds in the trust account are generally protected from third-party claims, but there is a risk that claims could reduce the per-share redemption amount if waivers are unenforceable or the sponsor's indemnity is insufficient. The company's ability to pay debts is contingent on successful financing and business combination.

Next Steps

• Complete the initial business combination within 24 months from the closing of the offering.
• Identify potential acquisition targets in the pharmaceutical industry, leveraging existing relationships and market research.
• Apply to list units, ordinary shares, and rights on The Nasdaq Global Market (Nasdaq) under symbols DMIIU, DMII, and DMIIR, respectively.
• File a Current Report on Form 8-K with the SEC, including an audited balance sheet, promptly after the closing of the offering.
• Conduct in-depth due diligence on prospective target businesses after signing a letter of intent or preliminary agreement.
• Establish and maintain an audit committee and compensation committee, and adopt a Code of Conduct and clawback policy.
• Maintain directors and officers insurance until the earlier of business combination completion or liquidation.

Key Dates

Recommendation

The company is a blank check company with no operations, making it a speculative investment. While the management team has relevant industry experience and a clear strategy to address critical U.S. pharmaceutical supply chain issues, significant risks exist. These include substantial dilution for public shareholders from founder shares, potential conflicts of interest due to management's involvement in another SPAC and prior business issues (Bright Green Corp. Chapter 11 and litigation), and the inherent uncertainty of completing a suitable business combination within the 24-month window. The deferred underwriting commissions also create an incentive for underwriters to push for a deal. Investors should monitor the company's progress in identifying a target and resolving existing legal matters before making a more definitive investment decision.

Keywords

SPAC, Pharmaceutical Industry, Blank Check Company, IPO, SEC Filing, Merger, Acquisition, Cayman Islands, Trust Account, Dilution, Corporate Governance, Risk Factors, Supply Chain Resilience, Domestic Manufacturing, Active Pharmaceutical Ingredients, Generic Drugs, Nasdaq Listing, Lynn Stockwell, Bright Green Corporation, Chapter 11, Litigation, Conflicts of Interest, Underwriting, Private Placement